Scientists have finally solved a 50-year mystery by discovering exactly how bacteria make sinefungin, a powerful cancer-fighting drug. According to Gram Research analysis, the key breakthrough is that a vitamin B12-powered enzyme—not the previously assumed enzyme—builds sinefungin’s critical structure through an unusual radical chemical reaction. Researchers successfully recreated this process in the laboratory, opening new possibilities for producing this medicine more efficiently.
For decades, scientists couldn’t figure out how nature makes sinefungin, a powerful molecule that fights cancer and other diseases. Now, researchers have finally cracked the code by discovering the exact steps bacteria use to build this medicine. They found that an unusual enzyme powered by vitamin B12 does the heavy lifting, and they’ve even figured out how to make sinefungin in the lab using these natural recipes. This breakthrough could help scientists design new medicines and understand how our bodies make other important compounds.
Key Statistics
A 2026 research study published in the Journal of the American Chemical Society revealed that sinefungin biosynthesis relies on a vitamin B12-dependent radical SAM enzyme, overturning decades of scientific assumptions about how this cancer-fighting molecule is naturally produced.
Researchers discovered that peptide aminoacyl-tRNA ligases (PEARLs) can iteratively attach multiple amino acids to sinefungin’s nucleoside scaffold, demonstrating a novel function for these enzymes beyond their traditional role in protein synthesis.
The study demonstrated that bacteria use a phosphorylation-dephosphorylation strategy to prevent sinefungin from accumulating inside cells where it would be toxic, revealing an elegant safety mechanism in the biosynthetic pathway.
The Quick Take
- What they studied: How bacteria naturally produce sinefungin, a powerful antimetabolite drug that mimics an important molecule in our cells called SAM
- Who participated: Laboratory research using bacteria (Streptomyces incarnatus) and enzyme studies; no human participants
- Key finding: Scientists discovered that a vitamin B12-powered enzyme builds sinefungin through an unusual chemical reaction, not the previously assumed process, and they successfully recreated this in the lab
- What it means for you: This discovery could lead to cheaper, easier ways to produce sinefungin and similar medicines for cancer and other diseases, though it’s still early-stage research far from patient use
The Research Details
Researchers studied bacteria that naturally make sinefungin and identified all the genes responsible for its production. They then performed detailed laboratory experiments to understand exactly how each enzyme works, using special labeled molecules to trace the chemical reactions step-by-step. Finally, they recreated the entire sinefungin-making process in test tubes using only the purified enzymes they discovered.
This approach is like reverse-engineering a recipe: first finding all the ingredients and equipment in nature, then figuring out exactly how they combine, and finally proving you can make the same dish in your own kitchen. The researchers used advanced techniques including isotope labeling (marking atoms with special versions to track them) and genetic analysis to confirm their findings.
The study focused on understanding the complete biological pathway, which is the series of chemical steps that transform simple building blocks into the final medicine. This foundational knowledge is essential before scientists can optimize production or create improved versions of the drug.
Understanding how nature makes medicines is crucial because it reveals the most efficient and elegant chemical solutions that evolution has already discovered. This knowledge allows scientists to either copy nature’s methods or improve upon them. The discovery that vitamin B12 powers this reaction was surprising and opens new possibilities for making other medicines using similar strategies.
This research was published in the Journal of the American Chemical Society, a top-tier chemistry journal, indicating rigorous peer review. The study combined multiple complementary approaches (genetic analysis, biochemical testing, and synthetic recreation) which strengthens confidence in the findings. The use of isotope-labeled molecules provides direct evidence for the proposed chemical mechanisms. However, this is fundamental research conducted in laboratory conditions, not yet tested in living organisms or patients.
What the Results Show
The research revealed that sinefungin is built through a series of enzymatic steps orchestrated by genes in the bacteria. The most surprising discovery was that the critical carbon-carbon bond—the key connection that gives sinefungin its structure—is formed by a vitamin B12-dependent enzyme, not the pyridoxal phosphate (PLP) enzyme that scientists had hypothesized for decades. This vitamin B12-powered enzyme works through an unusual radical mechanism, meaning it uses highly reactive molecular fragments to rearrange atoms.
The team also discovered that the adenosyl group (a crucial part of sinefungin) comes from adenosylcobalamin, a form of vitamin B12, and is incorporated through an atypical chemical reaction called homolytic SH2 substitution. This mechanism was previously unknown in this type of chemistry.
Additionally, the researchers identified two special enzymes called PEARLs (peptide aminoacyl-tRNA ligases) that attach amino acids to the growing sinefungin molecule. Remarkably, these enzymes normally work on large protein-making machinery but here function on small molecules instead. One PEARL enzyme can even add multiple amino acids in sequence, like beads on a string.
Finally, the team successfully recreated sinefungin synthesis in test tubes using only the purified enzymes, proving their understanding was correct and demonstrating that this natural recipe can be reproduced outside living cells.
The research uncovered a clever safety mechanism: the pathway uses a phosphorylation-dephosphorylation strategy (adding and removing phosphate groups) that prevents sinefungin from accumulating inside bacterial cells where it would be toxic. This explains why certain intermediates in the pathway are phosphorylated—it’s a protective measure. The team also performed substrate profiling, discovering that multiple enzymes in the pathway specifically recognize phosphorylated versions of their targets, which explains why this chemical modification strategy is so important.
For over 50 years since sinefungin’s discovery in the 1970s, scientists assumed the critical carbon-carbon bond was formed by a PLP-dependent enzyme, a common type of enzyme in nature. This study definitively overturns that assumption, showing instead that vitamin B12 powers this reaction. This finding is significant because it expands our understanding of what vitamin B12 can do in biological systems and reveals a previously underappreciated role for radical chemistry in natural product synthesis. The discovery of PEARL enzymes working on small molecules rather than proteins also represents a novel function for this enzyme family.
This research is fundamental biochemistry conducted entirely in laboratory settings using purified enzymes and bacterial cultures. It has not been tested in living animals or humans, so we cannot yet know if these findings will translate to practical medicine production. The study doesn’t address whether this method could be scaled up to industrial levels or whether it would be cost-effective compared to current sinefungin production methods. Additionally, while the researchers successfully recreated sinefungin synthesis in vitro, optimization of this process for practical applications remains future work. The research also doesn’t explore potential applications or safety of sinefungin itself, focusing only on how it’s made.
The Bottom Line
This research provides strong evidence (high confidence) that vitamin B12-dependent enzymes can be harnessed to produce sinefungin and similar molecules. Scientists should pursue further optimization of the enzyme cascade for practical production. However, this is not yet ready for clinical application—additional research is needed to scale production, test safety, and determine efficacy in living systems.
Pharmaceutical chemists and biotechnology companies interested in producing sinefungin or similar nucleoside analogs should pay attention to these findings. Researchers studying vitamin B12 chemistry and radical-mediated reactions will find this work valuable. Cancer researchers and infectious disease specialists may eventually benefit if this leads to improved sinefungin production. This research is not directly relevant to patients at this stage, as it’s foundational science, not a clinical advancement.
This is early-stage research. Moving from laboratory enzyme synthesis to practical drug production typically takes 5-10 years. Clinical testing, if pursued, would add another 5-10 years. Realistic timeline for potential patient benefit: 10-20 years, assuming this research direction is pursued and proves successful.
Frequently Asked Questions
How is sinefungin made in nature and why does it matter?
Bacteria make sinefungin through a series of enzymatic steps powered by vitamin B12. This matters because understanding nature’s recipe allows scientists to produce this cancer-fighting drug more efficiently in laboratories, potentially making it cheaper and more accessible as a medicine.
What is vitamin B12’s role in making sinefungin?
Vitamin B12 powers a special enzyme that creates the critical carbon-carbon bond in sinefungin through an unusual radical reaction. This was surprising because scientists previously thought a different enzyme type did this job, expanding our understanding of what vitamin B12 can accomplish.
Can scientists now produce sinefungin in the lab instead of extracting it from bacteria?
Yes, researchers successfully recreated sinefungin synthesis using purified enzymes in test tubes, proving the concept works. However, scaling this up to industrial production and optimizing it for cost-effectiveness requires additional research and development.
When will this discovery lead to better sinefungin medicines for patients?
This is early-stage research, so practical applications are likely 10-20 years away. Scientists must first optimize production methods, then conduct safety and efficacy testing before any new sinefungin-based treatments could reach patients.
What makes this research different from previous sinefungin studies?
This is the first study to completely map out all genes and enzymes involved in sinefungin production and prove the mechanism works in the laboratory. Previous research couldn’t identify the complete pathway or explain how the critical chemical bond actually forms.
Want to Apply This Research?
- While this research doesn’t directly apply to personal health tracking, users interested in biochemistry or pharmaceutical development could track their learning progress through related topics: bookmark this article, track related research papers read, and monitor understanding of enzyme catalysis concepts.
- This research is educational rather than behavioral. Users could engage by: learning about vitamin B12’s roles in the body, exploring how medicines are made from natural sources, or following pharmaceutical biotechnology developments. Consider setting reminders to check for updates on sinefungin clinical trials.
- For those interested in this research area, establish a long-term monitoring strategy by: subscribing to Journal of the American Chemical Society updates, following pharmaceutical biotechnology news, tracking sinefungin research developments, and monitoring when this technology might transition from laboratory to clinical applications.
This research describes fundamental laboratory science focused on how bacteria produce sinefungin. It does not evaluate sinefungin’s safety, efficacy, or suitability as a medicine for any condition. Sinefungin is a research compound and is not approved for human use. Any potential medical applications are years away from clinical reality. This article is for educational purposes only and should not be interpreted as medical advice. Consult qualified healthcare providers regarding any medical concerns or treatment options.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.